101 related articles for article (PubMed ID: 10620464)
1. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
Nagourney RA
Gynecol Oncol; 2000 Jan; 76(1):143. PubMed ID: 10620464
[No Abstract] [Full Text] [Related]
2. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE
Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
[TBL] [Abstract][Full Text] [Related]
3. Correlation between in vitro drug response in the EDR assay and response to primary paclitaxel and cisplatin.
DiSaia PJ
Gynecol Oncol; 1999 Jul; 74(1):148-9; author reply 149-50. PubMed ID: 10385571
[No Abstract] [Full Text] [Related]
4. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
5. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
6. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
[TBL] [Abstract][Full Text] [Related]
7. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
8. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy for ovarian cancer.
Cvitkovic E; Misset JL
N Engl J Med; 1996 May; 334(19):1269; author reply 1270. PubMed ID: 8606730
[No Abstract] [Full Text] [Related]
10. [Efficacy and toxicity of a taxotere/cisplatin combination in first line chemotherapy in patients with disseminated ovarian cancer].
Gorbunova VA; Khokhlova SV; Besova NS; Orel NF; Kuznetsov VV; Bliumenberg AG; Smirnova NB; Chekalova MA; Sinitsyna ME; Poddubnyĭ BK
Vopr Onkol; 2001; 47(5):1-6. PubMed ID: 11799946
[No Abstract] [Full Text] [Related]
11. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
13. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacotherapy in ovarian carcinoma].
Pfisterer J; Du Bois A
MMW Fortschr Med; 2005 Oct; 147(43):34-6. PubMed ID: 16302419
[TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal therapy of ovarian cancer.
Markman M
Semin Oncol; 1998 Jun; 25(3):356-60. PubMed ID: 9633848
[TBL] [Abstract][Full Text] [Related]
16. [Ovarian cancer treatment from the standpoint of the gynecologic oncologist].
Sugiyama T; Yoshizaki A; Hatayama S
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1011-6. PubMed ID: 17637537
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel and cisplatin in ovarian cancer.
Torri V; Harper PG; Colombo N; Sandercock J; Parmar MK
J Clin Oncol; 2000 Jun; 18(11):2349-51. PubMed ID: 10829060
[No Abstract] [Full Text] [Related]
18. Cisplatin-paclitaxel-cyclophosphamide with G-CSF in primary advanced epithelial ovarian cancer.
Fanning J; Colgrove M; Phibbs G
Gynecol Oncol; 2000 Oct; 79(1):97-100. PubMed ID: 11006039
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
20. Surgical response of advanced-stage borderline ovarian tumors to paclitaxel and cisplatin chemotherapy.
Eltabbakh GH; Srivastava A; Garafano LL
Gynecol Oncol; 2000 May; 77(2):343-4. PubMed ID: 10785499
[No Abstract] [Full Text] [Related]
[Next] [New Search]